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Embase, Scielo and LILACS using the key words “multiple sclerosis” and “esclerosis 
múltiple” plus “Latin America” and all country names. Full articles or abstracts from 
meetings reporting original research on cost or economic analyses, budget impact 
or resource utilization were obtained. No restrictions were placed on publication 
date or language. All work was done in duplicate by two independent reviewers 
with adjudication by consensus discussion. Results: We identified 1482 papers, 
of which 27 were considered for analysis. There were 7 economic analyses (5 cost-
effectiveness, 2 cost-utility), 5 budget impact analyses, 10 cost analyses (6 drug 
expenditures and 4 cost of illness), 4 on resource utilization and 1 on productivity 
loss. Studies were obtained from 5 countries (18 Brazil, 3 Argentina, 3 Colombia, 2 
Mexico, 1 Chile). Mostly (22/27, 81%) were published as abstracts; 5 were published 
as full text articles (19%). Dates for these publications ranged from 2002 to 2013, 
with an exponential increase over time. The number of MS patients is increasing 
rapidly (71% increase in Brazil between 2006 and 2009). However, hospitalization 
rates (overall and per patient) have been decreasing, as newer more effective drugs 
have been increasingly used. Disease modulating therapies are predominantly 
used. Costs of care are quite high and have risen dramatically, e. g. > 200% in Brazil 
between 2007-2012, with beta-interferons mostly used (78%). Some high cost drugs 
such as fingolimod and natalizumab have been found cost-effective over older drugs 
such as beta-interferons or glatiramer acetate in Mexico, Brazil and Colombia, with 
modest impact on budgets. ConClusions: Very little evidence related to cost of 
MS has been produced in Latin America. More research is needed to better support 
decisions regarding care of MS patients.
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objeCtives: Alzheimer’s disease has a substantial economic impact on patients, 
their caregivers and society. There are four cognitive enhancers commonly used in 
the treatment of Alzheimer’s disease: three cholinesterase inhibitors (donepezil, 
rivastigmine and galantamine) and one NMDA receptor antagonist (memantine). 
Studies have indicated that the cost of cholinesterase treatment may be offset by 
savings in other health care costs. Methods: The cost of medication on the South 
African market for Alzheimer’s disease was analysed using June 2014 retail prices 
with the Defined Daily Dose (DDD) as unit cost indicator. A retrospective drug uti-
lisation study was conducted on prescription data of a medical insurance scheme 
administrator for 2012. Results: The cost per DDD for memantine was R26.20 
(20 mg, two 10 mg tablets). For rivastigmine, the cost was R41.02 per DDD and for 
galantamine R27.72 per DDD (using the most convenient dosage strengths). These 
three products were all originator products. For donepezil, the originator and three 
branded generics were available. The cost of the originator was R27.86 per DDD, and 
for all three generics R16.29 per DDD. Only 32 patients were included in the drug 
utilisation study since not all medical aids reimburse these products. The aver-
age age of patients was 74.17 (SD= 9.54) years, with 50% females. Only memantine 
and donepezil were prescribed. Donepezil accounted for 77.48% of prescriptions 
(of which 60.93% were generic prescriptions). The average Prescribed Daily Doses 
(PDDs) were 16.30 (SD= 4.92) mg for memantine and 8.73 (SD= 2.84) mg for donepezil. 
The most frequent PDDs for memantine was 20 mg (62.96% of prescriptions) and 
10 mg (37.04% of prescriptions), and for donepezil 10 mg (65.96% of prescriptions) 
and 5 mg (29.79% of prescriptions). ConClusions: More South African studies on 
Alzheimer’s disease treatment cost are needed that include the stage of the disease 
and adherence to treatment.
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objeCtives: Several commonly prescribed enzyme-inducing anti-epileptic drugs 
(EIAEDs) stimulate the synthesis of some hepatic enzymes responsible for drug 
metabolism. This synthesis can lead to complications by altering endogenous 
metabolic pathways or by affecting the elimination of concomitant drugs thus 
increasing health care costs. This study aimed to systematically review published 
estimates of direct and indirect costs associated with the use of EIAEDs compared 
with non-enzyme-inducing anti-epileptic drugs (nEIAEDs) in patients with focal 
and generalised seizures, and to evaluate methodological differences between the 
studies. Methods: Comprehensive electronic searches were undertaken using 
MEDLINE, EMBASE, Cochrane Library, EconLit, relevant conference proceedings 
and cost effectiveness analysis registries. All studies reporting any direct and 
indirect costs of AEDs for the treatment of patients with epileptic seizures were 
included. Study quality assessment was performed for every included study 
using a predesigned check list. Results: Thirty-seven full-length articles and 
two abstracts reporting costs were reviewed. Two studies reported AED costs, 
drug-specific adverse event costs and non-drug health care costs subsequent to 
the initiation of each individual AED (medical visits, MRI scans, etc.). Six studies 
reported specific AED costs and the overall subsequent non-drug health care cost 
without stratification by event. Eighteen studies reported AED acquisition costs 
but did not report any other subsequent AED-related health care costs stratified 
by treatment. Thirteen studies reported the whole cost of illness with only a list 
of AEDs included. To date, no study has been specifically designed to compare 
the total costs between EIAED and nEIAED use, although some studies compared 
direct and indirect costs of several newer AEDs versus older AEDs. ConClusions: 
Insufficient data and heterogeneity in methodology prevent valid comparisons 
being made between the total cost of EIAEDs and nEIAEDs. More research is 
required to identify if meaningful differences in the total cost of treatment exist 
between EIAEDs and nEIAEDs.
This analysis aimed to assess if the early switch from IFNB to fingolimod impacts 
MS clinical outcomes and promotes better resource utilization in a Portuguese 
hospital perspective. Methods: This analysis was based on TRANSFORMS phase 
III trial extension data. A cost-effectiveness model was developed to calculate the 
cost per relapse avoided with 4.5 years of continuous treatment with fingolimod 
(early treatment) versus 1 year of treatment with IFNB followed by a 3.5 years of 
treatment with fingolimod (delayed treatment). A Portuguese hospital perspec-
tive was adopted addressing only direct costs: drug, monitoring and relapses’ 
treatment. Drug costs were based on Portuguese list prices, while the unit cost 
of each complication was obtained from the Diagnosis Related Groups tariff. The 
costs of relapses were derived from the Portuguese literature. Results: Assuming 
there are 819 patients treated with IFNB that are poor responders, the early treat-
ment with fingolimod resulted in more relapses avoided when compared with 
delayed treatment with fingolimod (2,211 versus 1,843). The early treatment with 
fingolimod led to an increase of drug acquisition costs, but reduced costs asso-
ciated to monitoring and relapses’ treatment. The total costs were 86,380,820€ 
for early treatment versus 79,257,091€ for delayed treatment. This represents an 
average incremental investment of 1,933€ per patient per year. The early strategy 
resulted an incremental cost effectiveness ratio of 19,358€ per relapse avoided 
when compared with the delayed strategy. ConClusions: Under the Portuguese 
hospital perspective, early treatment with fingolimod is expected to result in 
better clinical outcomes associated with a more efficient health care resources 
allocation.
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objeCtives: Intrathecal baclofen (ITB) therapy is indicated for use in the manage-
ment of intractable spasticity. Patients treated with ITB are required to receive a 
pump refill at least once every three months in the hospital (standard care (SC)). 
Since SC can be very burdensome for both patients and informal caregivers, an 
alternative approach (Care4homecare) has been developed which enables patients 
to receive pump refills at home. Moreover, the use of specially trained nurse prac-
titioners ensures that there is no reduction in effectiveness. We compared the 
costs of both strategies. Methods: Resource use in both strategies was estimated 
using observational data of 38 adult patients with spasticity (due to e. g. multiple 
sclerosis or spinal cord injury) that are currently living at home. We then com-
bined this data with expert opinion and the Dutch costing manual to estimate 
the total one-year costs from a societal perspective. Results: Patients included 
in the analysis had on average an age of 52±14.4 years, 50% was men and patients 
scored on average 44±12.5 points on the Care Dependency Scale. The Care4homecare 
strategy involves care that is almost identical to SC and therefore can result in 
comparable direct medical costs. However, patients receiving Care4homecare do 
not incur any travel costs compared with SC patients (€ 489). In addition, the pro-
ductivity costs of informal caregivers (SC € 195; Care4homecare € 40) and of patients 
treated with Care4homecare are less than the costs of patients receiving SC. From 
a societal perspective, the total costs of Care4homecare can be lower than that of 
SC. ConClusions: Care4homecare is an alternative approach to treat patients 
with intrathecal baclofen that can be cost-neutral from a health care sector per-
spective and cost-saving from a societal perspective. Moreover, it can be a welcome 
option for many patients and caregivers who want to avoid the burden of regular 
hospital visits.
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objeCtives: To analyze the costs associated with first-line use of glatiramer acetate 
(GA) compared to interferon-B (INF-β ) in patients with relapsing-remitting multiple 
sclerosis (RRMS) and spasticity from the perspective of the National Health System 
of Spain. Methods: A cost analysis of treatment and spasticity management with 
INF-β compared to GA for 6 months were analyzed. The clinical data were taken from 
the ESCALA study, which showed an improvement in spasticity in terms of spasm 
frequencies, muscle tone, and pain 3 and 6 months after the start of GA therapy. 
Unit costs for the resources used were taken from the BOTPLUS 2.0 database and 
available literature. The cost analysis is expressed in euros as of 2014, and a price 
discount of 7.5% was applied as set forth in Spanish Royal Decree 8/2010. Results: 
The costs associated with the management of RRMS, spasticity, and relapses using 
GA and INF-β were € 4,671.31 and € 7,078.02, respectively, generating a cost savings 
of € 2,406.72/patient, in favour of GA. ConClusions: The use of AG in the first-
line treatment of patients with RRMS not only improves spasticity but it could be 
a strategy that offers savings cost after 6 months from the start of treatment. To 
initiate the treatment with AG and keep it in patients with optimal response would 
be a more efficient treatment option than INF-β .
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objeCtives: To summarize published articles dealing with economic issues related 
to multiple sclerosis (MS) in Latin America. Methods: We searched Medline, 
